Reported Consolidated quarterly numbers for Ind-Swift Laboratories are: Net Sales at Rs 11.96 crore in September 2024 down 95.87% from Rs. 289.71 crore in September 2023. Quarterly Net Profit at Rs. 0.41 crore in September 2024 down 98.69% from Rs. 31.66 crore in September 2023. EBITDA stands at Rs. 1.21 crore in September 2024 down 98.34% from Rs. 73.09 crore in September 2023.
Open FlipReported Consolidated quarterly numbers for Natco Pharma are: Net Sales at Rs 1,371.10 crore in September 2024 up 32.94% from Rs. 1,031.40 crore in September 2023. Quarterly Net Profit at Rs. 677.30 crore in September 2024 up 83.55% from Rs. 369.00 crore in September 2023. EBITDA stands at Rs. 868.10 crore in September 2024 up 78.11% from Rs. 487.40 crore in September 2023.
Open FlipReported Consolidated quarterly numbers for Marksans Pharma are: Net Sales at Rs 641.92 crore in September 2024 up 20.84% from Rs. 531.24 crore in September 2023. Quarterly Net Profit at Rs. 96.72 crore in September 2024 up 15.8% from Rs. 83.52 crore in September 2023. EBITDA stands at Rs. 146.74 crore in September 2024 up 10.38% from Rs. 132.94 crore in September 2023.
Open Flip